Cargando…
Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437267/ https://www.ncbi.nlm.nih.gov/pubmed/36060000 http://dx.doi.org/10.3389/fphar.2022.974775 |
_version_ | 1784781559739449344 |
---|---|
author | Han, Jingxuan Luo, Lailiu Wang, Yicheng Wu, Shourong Kasim, Vivi |
author_facet | Han, Jingxuan Luo, Lailiu Wang, Yicheng Wu, Shourong Kasim, Vivi |
author_sort | Han, Jingxuan |
collection | PubMed |
description | Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and regions for treating high-altitude sickness, anoxia, resisting stress or fatigue, and for promoting longevity. Salidroside, a phenylpropanoid glycoside, is the main active component found in all species of Rhodiola. Salidroside could enhance cell survival and angiogenesis while suppressing oxidative stress and inflammation, and thereby has been considered a potential compound for treating ischemia and ischemic injury. In this article, we highlight the recent advances in salidroside in treating ischemic diseases, such as cerebral ischemia, ischemic heart disease, liver ischemia, ischemic acute kidney injury and lower limb ischemia. Furthermore, we also discuss the pharmacological functions and underlying molecular mechanisms. To our knowledge, this review is the first one that covers the protective effects of salidroside on different ischemia-related disease. |
format | Online Article Text |
id | pubmed-9437267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94372672022-09-03 Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases Han, Jingxuan Luo, Lailiu Wang, Yicheng Wu, Shourong Kasim, Vivi Front Pharmacol Pharmacology Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and regions for treating high-altitude sickness, anoxia, resisting stress or fatigue, and for promoting longevity. Salidroside, a phenylpropanoid glycoside, is the main active component found in all species of Rhodiola. Salidroside could enhance cell survival and angiogenesis while suppressing oxidative stress and inflammation, and thereby has been considered a potential compound for treating ischemia and ischemic injury. In this article, we highlight the recent advances in salidroside in treating ischemic diseases, such as cerebral ischemia, ischemic heart disease, liver ischemia, ischemic acute kidney injury and lower limb ischemia. Furthermore, we also discuss the pharmacological functions and underlying molecular mechanisms. To our knowledge, this review is the first one that covers the protective effects of salidroside on different ischemia-related disease. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9437267/ /pubmed/36060000 http://dx.doi.org/10.3389/fphar.2022.974775 Text en Copyright © 2022 Han, Luo, Wang, Wu and Kasim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Han, Jingxuan Luo, Lailiu Wang, Yicheng Wu, Shourong Kasim, Vivi Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title | Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title_full | Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title_fullStr | Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title_full_unstemmed | Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title_short | Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
title_sort | therapeutic potential and molecular mechanisms of salidroside in ischemic diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437267/ https://www.ncbi.nlm.nih.gov/pubmed/36060000 http://dx.doi.org/10.3389/fphar.2022.974775 |
work_keys_str_mv | AT hanjingxuan therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases AT luolailiu therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases AT wangyicheng therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases AT wushourong therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases AT kasimvivi therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases |